Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
N/A
1(33.3%)
Early Phase 1
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05595538Early Phase 1Completed

Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19

Role: collaborator

NCT04951349Phase 2Completed

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.

Role: collaborator

NCT02911740Not ApplicableWithdrawn

Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama

Role: collaborator

All 3 trials loaded